Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | MMP8 | P22894 | 4/20 | 0.47 |
| ▸ | FDPS | P14324 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 2/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3805248 | 0.87 | SMN1; SMN2 (0.59) | SMN1; SMN2HIF1AMMP8FDPSCYP2C9 | |
| Lithium SCHEMBL8632590 | 0.85 | SMN1; SMN2 (0.57) | SMN1; SMN2HIF1AMMP8FDPSCYP2C9 | |
| SCHEMBL16781446 | 0.80 | SMN1; SMN2 (0.57) | SMN1; SMN2HIF1AMMP8FDPSCYP2C9 | |
| SCHEMBL9736276 | 0.80 | SMN1; SMN2 (0.57) | SMN1; SMN2HIF1AMMP8FDPSCYP2C9 | |
| SCHEMBL27775684 | 0.79 | SMN1; SMN2 (0.50) | SMN1; SMN2HIF1AMMP8FDPSCYP2C9 | |
| SCHEMBL16019075 | 0.79 | ALDH1A1 (0.60) | SMN1; SMN2HIF1AMMP8ALDH1A1TAAR1 | |
| SCHEMBL5691293 | 0.78 | AKR1B1 (0.48) | HIF1AALDH1A1TAAR1AKR1B1CYP2D6 | |
| SCHEMBL2927672 | 0.78 | SMN1; SMN2 (0.48) | SMN1; SMN2HIF1AMMP8FDPSCYP2C9 | |
| SCHEMBL7434259 | 0.78 | SMN1; SMN2 (0.53) | SMN1; SMN2HIF1AMMP8FDPSCYP2C9 | |
| SCHEMBL7939924 | 0.77 | SMN1; SMN2 (0.53) | SMN1; SMN2HIF1AMMP8FDPSCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160090353-A1 | PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2016-03-31 | — | — | US | disclosed |
| US-9238616-B2 | Prodrugs of gaba analogs, compositions and uses thereof | XENOPORT, INC. (US) | 2016-01-19 | — | — | US | disclosed |
| US-20150307442-A1 | PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF | ARBOR PHARMACEUTICALS, LLC | 2015-10-29 | — | — | US | disclosed |
| US-20130102641-A1 | PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2013-04-25 | — | — | US | disclosed |
| US-8367722-B2 | Methods of using prodrugs of pregabalin | XENOPORT, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8168623-B2 | Prodrugs of GABA analogs, compositions and uses thereof | XENOPORT, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| CN-101381339-B | Prodrugs of gaba analogs, compositions and uses thereof | XENOPORT INC | 2012-03-07 | — | — | CN | disclosed |
| US-20120035258-A1 | METHODS OF USING PRODRUGS OF PREGABALIN | XENOPORT, INC. (US) | 2012-02-09 | — | — | US | disclosed |
| EP-1902714-B1 | Prodrugs of gaba analogs, compositions and uses thereof | XENOPORT INC (US) | 2012-01-11 | — | — | EP | disclosed |
| US-8048917-B2 | Prodrugs of GABA analogs, compositions and uses thereof | XENOPORT, INC. (US) | 2011-11-01 | — | — | US | disclosed |
| US-6972341-B2 | Prodrugs of GABA analogs, compositions and uses thereof | XENO PORT, INC. (US) | 2005-12-06 | — | — | US | disclosed |
| EP-1569895-A1 | PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF | Xenoport, Inc. (US) | 2005-09-07 | — | — | EP | disclosed |
| EP-1404324-A4 | PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF | XENOPORT INC (US) | 2004-12-22 | — | — | EP | disclosed |
| US-6818787-B2 | FOR THERAPY AND PROPHYLAXIS OF EPILEPSY, DEPRESSION, ANXIETY, PSYCHOSIS, FAINTNESS ATTACKS, HYPOKINESIA, CRANIAL DISORDERS, NEURODEGENERATIVE DISORDERS, PANIC, PAIN, INFLAMMATORY DISEASE, INSOMNIA, GASTROINTESTINAL DISORDERS | XENOPORT, INC. | 2004-11-16 | — | — | US | disclosed |
| WO-2004052844-A1 | PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2004-06-24 | — | — | WO | disclosed |
| US-20040077553-A1 | Prodrugs of GABA analogs, compositions and uses thereof | XENOPORT, INC. | 2004-04-22 | — | — | US | disclosed |
| EP-1404324-A2 | PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF | Xenoport, Inc. (US) | 2004-04-07 | — | — | EP | disclosed |
| US-20040006132-A1 | Prodrugs of gaba analogs, compositions and uses thereof | ARBOR PHARMACEUTICALS, LLC | 2004-01-08 | — | — | US | disclosed |
| US-20030176398-A1 | Prodrugs of GABA analogs, compositions and uses thereof | HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT | 2003-09-18 | — | — | US | disclosed |
| WO-2002100347-A2 | PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160090353-A1 | PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF | GABRB1, GABRB2, GABRB3 | SMN1; SMN2 1234/4885HIF1A 1245/4885MMP8 4560/4885 |
| US-20150307442-A1 | PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF | GABRB1, GABRB2, GABRB3 | SMN1; SMN2 1234/4885HIF1A 1245/4885MMP8 4560/4885 |
| US-20040077553-A1 | Prodrugs of GABA analogs, compositions and uses thereof | GABRB1, GABRB2, GABRB3 | SMN1; SMN2 1234/4885HIF1A 1245/4885MMP8 4560/4885 |
| US-20040006132-A1 | Prodrugs of gaba analogs, compositions and uses thereof | GABRB1, GABRB2, GABRB3 | SMN1; SMN2 1234/4885HIF1A 1245/4885MMP8 4560/4885 |
| US-20120035258-A1 | METHODS OF USING PRODRUGS OF PREGABALIN | GABBR1, GABRB2, GABBR2 | SMN1; SMN2 2116/4885HIF1A 2175/4885MMP8 4751/4885 |
| US-20130102641-A1 | PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF | GABRB1, GABRB2, GABRB3 | SMN1; SMN2 1234/4885HIF1A 1245/4885MMP8 4560/4885 |
| US-20030176398-A1 | Prodrugs of GABA analogs, compositions and uses thereof | GABRB1, GABRB2, GABRB3 | SMN1; SMN2 1234/4885HIF1A 1245/4885MMP8 4560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.